Literature DB >> 33673227

Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet.

Victoria Svop Jensen1,2, Christian Fledelius2, Erik Max Wulff3, Jens Lykkesfeldt1, Henning Hvid4.   

Abstract

The use of translationally relevant animal models is essential, also within the field of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Compared to frequently used mouse and rat models, the hamster may provide a higher degree of physiological similarity to humans in terms of lipid profile and lipoprotein metabolism. However, the effects in hamsters after long-term exposure to a NASH diet are not known. Male Syrian hamsters were fed either a high-fat, high-fructose, high-cholesterol diet (NASH diet) or control diets for up to 12 months. Plasma parameters were assessed at two weeks, one, four, eight and 12 months and liver histopathology and biochemistry was characterized after four, eight and 12 months on the experimental diets. After two weeks, hamsters on NASH diet had developed marked dyslipidemia, which persisted for the remainder of the study. Hepatic steatosis was present in NASH-fed hamsters after four months, and hepatic stellate cell activation and fibrosis was observed within four to eight months, respectively, in agreement with progression towards NASH. In summary, we demonstrate that hamsters rapidly develop dyslipidemia when fed a high-fat, high-fructose, high-cholesterol diet. Moreover, within four to eight months, the NASH-diet induced hepatic changes with resemblance to human NAFLD.

Entities:  

Keywords:  animal models; dyslipidemia; hamster; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2021        PMID: 33673227      PMCID: PMC7917647          DOI: 10.3390/nu13020604

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  68 in total

Review 1.  The interaction of hepatic lipid and glucose metabolism in liver diseases.

Authors:  Lars P Bechmann; Rebekka A Hannivoort; Guido Gerken; Gökhan S Hotamisligil; Michael Trauner; Ali Canbay
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

2.  Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?

Authors:  Lisa M Glass; Christine M Hunt; Michael Fuchs; Grace L Su
Journal:  Fed Pract       Date:  2019-02

3.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 4.  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.

Authors:  W Nseir; A Shalata; A Marmor; N Assy
Journal:  Dig Dis Sci       Date:  2011-06-08       Impact factor: 3.199

Review 5.  Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Authors:  Kristen Stephenson; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2017-11-02

6.  Does non-alcoholic fatty liver impair alterations of plasma lipoproteins and associated factors in metabolic syndrome?

Authors:  Diego Lucero; Valeria Zago; Graciela I López; Mabel Graffigna; Gustavo H López; Hugo Fainboim; Verónica Miksztowicz; Leonardo Gómez Rosso; Susana Belli; Oscar Levalle; Gabriela Berg; Fernando Brites; Regina Wikinski; Laura Schreier
Journal:  Clin Chim Acta       Date:  2010-12-13       Impact factor: 3.786

Review 7.  Molecular mechanisms regulating hormone-sensitive lipase and lipolysis.

Authors:  C Holm; T Osterlund; H Laurell; J A Contreras
Journal:  Annu Rev Nutr       Date:  2000       Impact factor: 11.848

8.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

Authors:  Stuart McPherson; Tim Hardy; Elsbeth Henderson; Alastair D Burt; Christopher P Day; Quentin M Anstee
Journal:  J Hepatol       Date:  2014-12-01       Impact factor: 25.083

Review 9.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

10.  IMM-H007, a new therapeutic candidate for nonalcoholic fatty liver disease, improves hepatic steatosis in hamsters fed a high-fat diet.

Authors:  Huijie Shi; Qingchun Wang; Liu Yang; Shouxia Xie; Haibo Zhu
Journal:  FEBS Open Bio       Date:  2017-08-29       Impact factor: 2.693

View more
  2 in total

1.  Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models.

Authors:  Sridhar Radhakrishnan; Steven F Yeung; Jia-Yu Ke; Maísa M Antunes; Michael A Pellizzon
Journal:  Curr Dev Nutr       Date:  2021-11-13

2.  Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China.

Authors:  Jingrui Wang; Zhenzhen Su; Yijin Feng; Ruihan Xi; Jiamin Liu; Peixi Wang
Journal:  BMC Gastroenterol       Date:  2021-12-19       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.